About Accent Microcell
Accent Microcell is a company based in Ahmedabad (India) founded in 2001. Accent Microcell has raised $1.5 million across 1 funding round from investors including Adwaitartha, Vivinseccom and Swarnali Advisors. The company has 147 employees as of April 06, 2024. Accent Microcell offers products and services including Microcrystalline Cellulose (MCC) and Cosmetic Excipients. Accent Microcell operates in a competitive market with competitors including Amster Microcell and NextGen Exsome, among others.
- Headquarter Ahmedabad, India
- Employees 147 as on 06 Apr, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Accent Microcell Limited
-
Annual Revenue
$31.02 M (USD)7.77as on Mar 31, 2025
-
Net Profit
$3.87 M (USD)9.6as on Mar 31, 2025
-
EBITDA
$4.91 M (USD)5.28as on Mar 31, 2025
-
Total Equity Funding
$1.5 M (USD)
in 1 rounds
-
Latest Funding Round
$1.5 M (USD), Seed
Aug 21, 2023
-
Investors
Adwaitartha
& 54 more
-
Employee Count
147
as on Apr 06, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Accent Microcell
Accent Microcell is a publicly listed company on the NSE with ticker symbol ACCENTMIC in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Accent Microcell
Accent Microcell offers a comprehensive portfolio of products and services, including Microcrystalline Cellulose (MCC) and Cosmetic Excipients.
Used for drug delivery in pharmaceuticals and texture in food
Enhances smoothness and quality in cosmetics products
People of Accent Microcell
Unlock access to complete
Funding Insights of Accent Microcell
Accent Microcell has successfully raised a total of $1.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.5 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $1.5M
-
First Round
First Round
(21 Aug 2023)
- Investors Count 55
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Seed - Accent Microcell | Valuation | Adwaitartha , Vivinseccom |
Investors in Accent Microcell
Accent Microcell has secured backing from 55 investors, including institutional and angel investors. Prominent investors backing the company include Adwaitartha, Vivinseccom and Swarnali Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
MA
Manoj Agarwal |
Co-founder of Innov8, active angel investor in Indian startups
|
Founded Year | Domain | Location |
Investments & Acquisitions by Accent Microcell
Financial Statements - Accent Microcell
Accent Microcell Comparisons
Competitors of Accent Microcell
Accent Microcell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amster Microcell and NextGen Exsome, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Produces excipients like microcrystalline cellulose for pharmaceutical and nutraceutical industries.
|
|
| domain | founded_year | HQ Location |
Offers exosome engineering, analysis, and purification services for industrial sectors.
|
Frequently Asked Questions about Accent Microcell
Accent Microcell was founded in 2001 and raised its 1st funding round 22 years after it was founded.
Accent Microcell is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
Manoj Patel is the current CEO of Accent Microcell.
Accent Microcell is a funded company, having raised a total of $1.5M across 1 funding round to date. The company's 1st funding round was a Seed of $1.5M, raised on Aug 21, 2023.
As of Apr 06, 2024, the latest employee count at Accent Microcell is 147.
Annual revenue of Accent Microcell is $31.02M as on Mar 31, 2025.
Accent Microcell Ltd. was established in 2001 in Ahmedabad, India, within the pharmaceutical sector. Microcrystalline cellulose is produced as a thickening agent, along with other excipient and derivative products. Manufacturing processes are guided by principles of integrity, discipline, and commitment. Operations focus on supplying these materials for various pharmaceutical applications.
Accent Microcell's top competitors include Amster Microcell and NextGen Exsome.
Accent Microcell offers Microcrystalline Cellulose (MCC) and Cosmetic Excipients.
Yes, Accent Microcell is publicly traded on NSE under the ticker symbol ACCENTMIC.
Accent Microcell has 55 investors. Key investors include Adwaitartha, Vivinseccom, Swarnali Advisors, Manoj Agarwal, and Utsav Pramodkumar Shrivastav.
The ticker symbol of Accent Microcell is ACCENTMIC on NSE.
The valuation of Accent Microcell is $9.29M as of Aug 2023.